Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study
Neurana Pharmaceuticals to Present at Piper Sandler Healthcare Conference
Neurana Pharmaceuticals Announces Publication in Pain Management
Neurana Pharmaceuticals to Present at American Society of Interventional Pain Physicians Meeting
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
Neurana Pharmaceuticals Appoints Georgia Erbez and Liz Cermak to Board of Directors
Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference
Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study
Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study
Neurana Pharmaceuticals to Present at Piper Sandler 32nd Annual Healthcare Conference
Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference
Neurana Pharmaceuticals to Present at Solebury Trout Private Company Showcase
Neurana Pharmaceuticals to Present at Upcoming Investor Conference
Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study